The many roles of ultrasound in breast malignancy.
Breast (Ultrasonic imaging)
|Author:||O'Connell, Avice M.|
|Publication:||Name: Applied Radiology Publisher: Anderson Publishing Ltd. Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 Anderson Publishing Ltd. ISSN: 0160-9963|
|Issue:||Date: Sept, 2009 Source Volume: 38 Source Issue: 9|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Ultrasound has multiple uses at various stages in the diagnosis of
breast cancer. These include targeted ultrasound for a mammographic
finding, targeted ultrasound for a clinical finding, image guidance for
biopsy and clip placement, "second look" ultrasound after
magnetic resonance imaging (MRI), and preoperative localization for
breast conservation surgery. Ultrasound also has proven value in
screening for breast cancer, but for several reasons discussed below,
ultrasound screening has limited use and acceptance at this time.
Screening ultrasound for breast cancer detection is not in widespread use for several reasons. It is time consuming and highly operator-dependent. It also produces a greater number of false-positive results than mammography. This in turn leads to more biopsies and thereby increased cost. This outcome was demonstrated in preliminary results from the American College of Radiology Imaging Network (ACRIN) 6666 trial. (1) This trial was designed to provide guidance for women and their doctors on the role of screening ultrasound. It was a multicenter trial with 21 teams in 3 countries. Whole-breast ultrasound was performed on 2800 high-risk women who were followed for 3 years. Preliminary results showed that 40 cancers were diagnosed, and 12 of those were demonstrated by ultrasound alone. However, the false-positive rate for combined mammographic and ultrasound imaging was 10.4% compared with 4.4% for mammography alone.
Targeted diagnostic ultrasound
Diagnostic ultrasound, also known as targeted ultrasound, is commonly performed for an abnormality detected on mammography, such as a mass or an asymmetric density. Use of ultrasound in the evaluation of palpable and non-palpable masses is extremely valuable and also cost effective in the management of BI-RADS 3, 4 and 5 lesions. If palpable masses appear benign, according to strict sonographic criteria and have no features suggestive of malignancy, then they can be managed with short-interval follow-up, rather than biopsy. (2)
The classic sonographic characteristics of malignancy include orientation with respect to the chest wall, shape, margin, echogenicity and acoustic transmission. Malignant features include nonparallel orientation, "taller than wide" dimensions, irregular shape or margin, hypoechoic internal echogenicity and posterior acoustic shadowing (Figure 1).
It is also good practice to evaluate the adjacent axilla when a highly suggestive BI-RADS 5 lesion is detected and biopsied. If the axillary node is positive for malignancy, this may avoid the need for sentinel-node biopsy and the resulting risk of lymphedema of the arm. Abnormal lymph nodes may be rounded rather than bean-shaped, have an asymmetrically thickened cortex and exhibit indentations or obliteration of the hilum. They are not necessarily enlarged (Figure 2).
Diagnostic ultrasound is also invaluable for palpable findings especially in the setting of dense-breast parenchyma with subtle or no mammographic findings (Figure 3). This situation may include the clinical finding of a discrete mass or a less-specific "thickening." The negative-predictive value (NPV) of a combination of negative mammography and negative ultrasound of a palpable finding is 99.8% (3) although another study showed a 5% incidence of cancer in patients with a clinical finding of thickening. (4)
If a mammographic or ultrasound finding is considered suspicious enough to warrant biopsy, i.e. a BI-RADS 4 or 5 lesion, ultrasound is the preferred method for image-guided biopsy (Figure 4). (5) There are 3 reasons for biopsy under ultrasound rather than stereotactic guidance:
1. Physically, ultrasound-guided biopsy is easier on the patient.
2. Ultrasound allows direct visualization of the actual biopsy and clip placement.
3. Ultrasound can also detect bleeding and monitor hematoma development immediately.
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
[FIGURE 3 OMITTED]
Ductal carcinoma in situ
Since most cases of ductal carcinoma in situ (DCIS) are detected due to micro-calcifications and only a small percentage manifest as soft-tissue density without calcifications, ultrasound does not play a role in the detection of DCIS. Stereotactic biopsy with specimen radiography is preferred for biopsy of clustered calcifications.
"Second look" ultrasound
Second-look ultrasound is performed after breast MRI demonstrates an area of enhancement which is occult to mammography (Figure 5).
Figure 5 is an example of a "targeted ultrasound," directed at the area of MRI enhancement. This approach includes BI-RADS 0 lesions requiring further evaluation, BI-RADS 3 lesions, for which short-interval follow-up is indicated, and BI-RADS 4 or 5 lesions requiring biopsy. Ultrasound-guided biopsy is not only physically easier but is less costly and more readily available for biopsies and follow-up than MRI and also does not require contrast enhancement. Also, seeral areas can more easily be biopsied at the same time. However, second-look ultrasound has limitations.
First of all, only about 25% of mammographically occult lesions seen on MRI are detected on ultrasound. Also, since the MRI is performed with the patient prone and the ultrasound is performed with the patient supine, it is not always clear that a sonographic finding correlates with a given MRI finding. However, a group in Toronto has tested a method of sonographic coregistration using a prone ultrasound table, which may become very useful in ultrasound evaluation and correlation with MRI findings. (6)
[FIGURE 4 OMITTED]
[FIGURE 5 OMITTED]
[FIGURE 6 OMITTED]
Ultrasound-guided wire localization (Figure 6) is the preferred method of management for masses seen on ultra sound. The benefits of ultrasound vs. mammographic localization include:
1. Direct visualization of the target lesion.
2. Obtaining the shortest distance possible from skin to lesion.
3. Making exact needle-length measurements.
4. Visualization of the passage of the needle through the mass followed by wire deployment and needle removal.
Occasionally, for a subtle lesion that may not be visible on specimen radiography, a tissue marker clip can be placed in the lesion at the time of localization (Figure 6) for subsequent specimen radiography to confirm removal.
Ultrasonographic strain imaging is being evaluated for distinguishing between benign and solid masses. This approach may reduce the number of benign biopsies, together with their cost and morbidity; but according to Burnside et al. "interobserver variability and image quality influence observer performance." (7) There will no doubt be other technical advances and new applications for ultrasound in the breast.
Breast ultrasound is highly operator-dependent and requires more physician involvement, input and time than the other breast imaging modalities of mammography and MRI. However, ultrasound has unique qualities that make it indispensable and invaluable in the breast imaging armamentarium.
* GE Logiq 9 ultrasound with an M12L 5-13 MHz matrix array linear transducer, and a GE Logiq E ultrasound with an ML 6-15 MHz matrix array linear transducer; GE Healthcare, Chalfont St. Giles, U.K.
* Philips iU22 ultrasound with L17-5 MHz and L12-5 MHz linear array transducers, and an HDI 5000 (SonoCT) ultrasound with an L12-5 MHz linear array transducer; Philips Medical Systems, Andover, MA.
* Mammotome EX vacuum-assisted biopsy system using the handheld 11 g probe, Ethicon Endo-Surgery Inc., Cincinnati, OH
* Bard Vacora vacuum-assisted biopsy system using a 14 g or 10 g probe, and
a Bard Monopty Biopsy Instrument 14 g, Bard Peripheral Vascular, Tempe, AZ
* Biopsy clips used: 14 g CorMARK and an 11 g MammoMARK, Ethicon Endo-Surgery, Cincinnati, OH; 17 g UltraClip II tissue marker ultrasound ribbon, Bard Peripheral Vascular, Tempe, AZ; and a 14 g Gel Mark UltraCor, SenoRx, Aliso Viejo, CA
(1.) Berg W, Blume J, Cormack J, et al. Combined screening with ultrasound and mammography vs. mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299:2151-2163.
(2.) Raza S, Chikarmane SA, Neilsen SS, et al. BI-RADS 3, 4, and 5 lesions: Value of US in management-follow-up and outcome. Radiology. 2008;248: 773-781.
(3.) Soo M, Rosen EL, Baker JA, et al. Negative predictive value of sonography with mammography in patients with palpable breast lesions. AJR. 2001; 177:1167-1170.
(4.) Kaiser J, Helvie MA, Blacklaw RL, et al. Palpable breast thickening: Role of mammography and US in cancer detection. Radiology. 2002;223:839-844.
(5.) Mainiero MB, Gareen IF, Bird CE, et al. Preferential use of sonographically guided biopsy to minimize patient discomfort and procedure time in a percutaneous image-guided breast biopsy program. J Ultrasound Med. 2002;21:1221-1226.
(6.) Causer P, Piron CA, Jong RA, Plewes DB. Preliminary in vivo validation of a dedicated breast MRI and sonographic coregistration imaging system. AJR. 2008:191:1203-1207.
(7.) Burnside E, Hall TJ, Sommer AM, et al. Differentiating benign from malignant solid breast masses with US strain Imaging. Radiology. 2007;245: 401-410.
Avice M. O'Connell, MD, FACR
Dr. O'Connell is Director of Women's Imaging and Associate Professor, Clinical Imaging Sciences, University of Rochester Medical Center, Rochester NY.
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|